Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lykos' MDMA-Assisted PTSD Therapy Receives NDA Acceptance
Details : MDMA (Midomafetamine) is a ring-substituted amphetamine analog with reinforcing psychoactive effects. It is a 5-HT2A receptor agonist, which is under development for posttraumatic stress disorder.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 02, 2024
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lykos Therapeutics Reorganizes After FDA Decision on Midomafetamine Capsules for PTSD
Details : MDMA (Midomafetamine) is a ring-substituted amphetamine analog with reinforcing psychoactive effects. It is a 5-HT2A receptor agonist, which is being evaluated for the treatment of PTSD.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 15, 2024
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Helena
Deal Size : $100.0 million
Deal Type : Series A Financing
Maps Public Benefit Corporation Announces Oversubscribed Series A Financing Renamed Lykos
Details : Funds support regulatory activities for MDMA-assisted PTSD therapy combining MDMA with psychological care.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Undisclosed
May 01, 2024
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Helena
Deal Size : $100.0 million
Deal Type : Series A Financing
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lykos Therapeutics Provides Update on FDA Advisory Meeting for MDMA-Assisted PTSD Therapy
Details : MDMA (Midomafetamine) is a ring-substituted amphetamine analog with reinforcing psychoactive effects. It is a 5-HT2A receptor agonist, FDA PDAC voted against for its use PTSD treatment.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
Details : MDMA (3,4-methylenedioxymethamphetamine) is a synthetic, psychoactive drug with a chemical structure similar to the stimulant methamphetamine and the hallucinogen mescaline being developed the treatment of for PTSD.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 13, 2023
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MAPS PBC Announces Submission of New Drug Application to the FDA for MDMA-Assisted Therapy for PTSD
Details : MDMA (3,4-methylenedioxymethamphetamine) is a 5-HT2A receptor agonist, small molecule drug candidate, which is currently being evaluated for the treatment of patients with Post-traumatic stress disorder.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MDMA (3,4-methylenedioxymethamphetamine) is a synthetic, psychoactive drug with a chemical structure similar to the stimulant methamphetamine and the hallucinogen mescaline.
Product Name : MDMA
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 30, 2021
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Food Effects on Bioavailability of MDMA in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 07, 2021
Lead Product(s) : Midomafetamine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable